L'épopée des insulines des années 1930 aux années 1980

[en] After the historical discovery of insulin in 1921, a landmark advance in the treatment of diabetes mellitus, substantial progresses were made from the 1930's to the 1980's to improve available insulin preparations. This article discusses three major advances: the development of depot insulins that allowed reducing the number of daily injections, the production of purified insulin preparations that diminished the rate of immune-allergic reactions and the replacement of animal insulins by human insulin produced by the DNA recombinant biotechnology that permitted an almost unlimited production of high quality insulin without the limitations of animal sources.
[fr] Après la découverte historique de l'insuline en 1921, véritable révolution dans le traitement du diabète sucré, des progrès sensibles ont été réalisés de 1930 à 1980 pour améliorer les préparations insuliniques disponibles. Cet article discute trois avancées importantes : la mise au point d'insulines à effet retard autorisant un espacement des injections, la fabrication de préparations insuliniques purifiées donnant moins de réactions immuno-allergiques et le remplacement des insulines d'origine animale par de l'insuline humaine produite par génie génétique permettant ainsi une production quasi illimitée d'insuline d'excellente qualité tout en s'affranchissant de la collecte des pancréas sources des insulines animales.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

SCHEEN, André ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques

Lefèbvre, Pierre ; Université de Liège - ULiège > Relations académiques et scientifiques (Médecine)

Language :

French

Title :

L'épopée des insulines des années 1930 aux années 1980

Alternative titles :

[en] The epic of insulins from the 1930’s to the 1980’s

Publication date :

2021

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Elsevier Masson, Paris, France

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 19 October 2021

Statistics

Number of views

53 (5 by ULiège)

Number of downloads

5 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Schlienger, J.L., Halimi, S., La découverte de l'insuline. Med Mal Metab 15 (2021), 7–14 15/3S.
Monnier, L., Colette, C., Owens, D.R., Caractéristiques des insulines lentes et rapides. Med Mal Metab 15 (2021), 3S32–3S51.
Owens, D.R., Matfin, G., Monnier, L., Basal Insulin Analogues in the Management of Diabetes Mellitus: What Progress Have We Made?. Diabetes Metab Res Rev 30:2 (2014), 104–119.
Hagedorn, H.C., Norman Jensen, B., Krarup, N.B., Protamine Insulinate. JAMA 106 (1936), 177–180.
Scott, D.A., Fisher, A.M., Studies on Insulin with Protamine. J Pharmacol Exp Ther 58 (1936), 78–92.
Himsworth, H.P., Protamine Insulin and Zinc Protamine Insulin. Br Med J 1:3975 (1937), 541–546.
Krayenbuhl, C., Rosenberg, T., Crystalline Protamine Insulin. Rep Steno Mem Hosp Nord Insulinlab 1 (1946), 60–73.
Izzo, J.L., Gabiga, A.M., Hoffmaster, J., Pharmacologic and Clinical Studies on Two New Types of Long-acting Insulins with Special Reference to Zinc Insulin Preparations (Novo): a Preliminary Report. Diabetes 2:5 (1953), 358–364.
Hallas-Moller, K., et al. The Lente Insulins. Diabetes 5:1 (1956), 7–14.
Weiler, J.M., Freiman, P., Sharath, M.D., et al. Serious Adverse Reactions to Protamine Sulfate: Are Alternatives Needed? J Allergy Clin Immunol., 75(2), 1985, 297–303.
Binder, C., Lauritzen, T., Faber, O., et al. Insulin Pharmacokinetics. Diabetes Care 7:2 (1984), 188–199.
Oakley, W., Hill, D., Oakley, N., Combined Use of Regular and Crystalline Protamine (NPH) Insulins in the Treatment of Severe Diabetes. Diabetes 15:3 (1966), 219–222.
The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med 1993;329(14): 977-86.
Benhamou, P.Y., Hanaire, H., Renard, E., Schémas thérapeutiques depuis le basal-bolus jusqu'à la boucle fermée. Med Mal Metab 15 (2021), 52–62 15/3S.
Pettus, J., Santos Cavaiola, T., Tamborlane, W.V., et al. The Past, Present, and Future of Basal Insulins. Diabetes Metab Res Rev 32:6 (2016), 478–496.
Heise, T., Mathieu, C., Impact of the Mode of Protraction of Basal Insulin Therapies on their Pharmacokinetic and Pharmacodynamic Properties and Resulting Clinical Outcomes. Diabetes Obes Metab 19:1 (2017), 3–12.
Alberti, K.G., Nattrass, M., Highly Purified Insulins. Diabetologia 15:2 (1978), 77–80.
Lapolla, A., Dalfra, M.G., Hundred Years of Insulin Therapy: Purified Early Insulins. Am J Ther 27:1 (2020), e24–e29.
Harwood, R., Insulin-binding Antibodies and « Spontaneous » Hypoglycemia. N Engl J Med 262 (1960), 978–989.
Schlichtkrull, J., Brange, J., Christiansen, A.H., et al. Monocomponent Insulin and its Clinical Implications. Horm Metab Res 5 (1974), 134–143.
Scheen, A., Scheen-Lavigne, M., Luyckx, A., Étude comparative des insulines Novo Monotard et Lente MC. Rev Med Liege 34:22 (1979), 923–927.
Mirouze, J., Orsetti, A., Schmouker, Y., et al. Diabète sucré. Son traitement par les insulines purifiées monocomposées. Nouv Presse Med 2 (1973), 1981–1985.
Scheen, A.J., Henrivaux, P., Jandrain, B., et al. Antiinsulin Antibodies and Metabolic Deterioration after Interruption of Continuous Subcutaneous Insulin Infusion. Diabetes Care 9:6 (1986), 673–674.
Radermecker, R.P., Renard, E., Scheen, A.J., Circulating Insulin Antibodies: Influence of Continuous Subcutaneous or Intraperitoneal Insulin Infusion, and Impact on Glucose Control. Diabetes Metab Res Rev 25:6 (2009), 491–501.
Richardson, T., Kerr, D., Skin-related Complications of Insulin Therapy: Epidemiology and Emerging Management Strategies. Am J Clin Dermatol 4:10 (2003), 661–667.
Kumar, D., et al. Insulin Antibodies: Reduction in Various Anti-insulin IgG Subclasses with Human Insulin Therapy. Horm Metab Res 25:7 (1993), 360–364.
Morihara, K., Oka, T., Tsuzuki, H., Semi-synthesis of Human Insulin by Trypsin-Catalysed Replacement of Ala-B30 by Thr in Porcine Insulin. Nature 280:5721 (1979), 412–413.
Markussen, J., Damgaard, U., Pingel, M., et al. Human Insulin (Novo): Chemistry and Characteristics. Diabetes Care 6 (1983), 4–8.
Castillo, M., Nemery, A., Verdin, E., et al. Circadian Profiles of Blood Glucose and Plasma Free Insulin during Treatment with Semisynthetic and Biosynthetic Human Insulin, and Comparison with Conventional Monocomponent Preparations. Eur J Clin Pharmacol 25:6 (1983), 767–771.
Luyckx, A.S., Daubresse, J.C., Jaminet, C., et al. Immunogenicity of Semisynthetic Human Insulin in Man. Long-term Comparison with Porcine Monocomponent Insulin. Acta Dia-betol Lat 23:2 (1986), 101–106.
Chance, R.E., Kroeff, E.P., Hoffmann, J.A., et al. Chemical, Physical, and Biologic Properties of Biosynthetic Human Insulin. Diabetes Care 14:2 (1981), 147–154.
Miller, W.L., Baxter, J.D., Recombinant DNA—a New Source of Insulin. Diabetologia 18:6 (1980), 431–436.
Riggs, A.D., et al. Bacterial Production of Human Insulin. Diabetes Care 4:1 (1981), 64–68.
Schernthaner, G., Immunogenicity and Allergenic Potential of Animal and Human Insulins. Diabetes Care 16 (1993), 155–165.